To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
46 Current news of Bayer Schering Pharma
rss
Lead Discovery Center and Bayer enter into license agreement covering a novel pharmaceutical lead structure
Out-licensing of the first pharmaceutical lead structure generated at the Lead Discovery Center for further development into a cancer therapy
04-21-2011
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer ...
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
10-14-2010
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ...
Bayer launches Betaferon in China
09-28-2010
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ...
IBA and Bayer Schering Pharma Sign Clinical Trial Supply Agreement for Alzheimer’s Disease Tracer
08-31-2010
IBA (Ion Beam Applications S.A.) announced that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular imaging compound in development for the detection of Alzheimer’s ...
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
08-06-2010
Bayer announced that a novel, convenient single-drug treatment approach with oral rivaroxaban met the primary efficacy endpoint of non-inferiority in the EINSTEIN-DVT Phase III clinical trial and showed an overall relative risk reduction compared to the current standard therapy in the ...
Bayer: YAZ approved in Japan for the treatment of dysmenorrhea
07-28-2010
Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea. YAZ is available in the US, Europe, Latin America and the ...
Algeta concludes agreements for the manufacture and supply of Alpharadin for future commercial sale
Triggers EUR 5 million milestone payment from Bayer Schering Pharma
07-23-2010
Algeta ASA has announced it has concluded two agreements for the manufacture and supply of Alpharadin for future commercial sale. Alpharadin (radium-223) is a novel, targeted alpha-pharmaceutical in clinical trials for treating bone metastases in cancer patients. The signing of these ...
Protagen Deepens Cooperation With Bayer Schering Pharma
06-11-2010
Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is ...
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization
05-10-2010
Bayer Schering Pharma AG announced that it has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA). A Phase III clinical program for ...
Algeta completes successful sample size re-estimation of pivotal ALSYMPCA trial
05-04-2010
Algeta ASA announced that the sample size re-estimation of its pivotal ALSYMPCA clinical trial, which was pre-planned for the first half of 2010, was completed on schedule. The sample size re-estimation confirmed that the current plan to recruit 750 patients into the ALSYMPCA study will meet ...
